Product Description
Bilirubin (bil-ih-ROO-bin) is a yellowish pigment that is made during the normal breakdown of red blood cells. Bilirubin passes through the liver and is eventually excreted out of the body. Higher than normal levels of bilirubin may indicate different types of liver or bile duct problems (Sourced from: https://www.mayoclinic.org/tests-procedures/bilirubin/about/pac-20393041)
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Australia | India | Pakistan | Taiwan
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Neuromyelitis Optica|Jaundice, Neonatal|Hyperbilirubinemia, Neonatal
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ChiCTR2400083378 | N/A |
Not yet recruiting |
Other |
2027-04-24 |
|
| ChiCTR2400084458 | N/A |
Not yet recruiting |
Liver Failure, Acute |
2026-05-09 |
|
| Multi-TCB | N/A |
Recruiting |
Hyperbilirubinemia, Neonatal |
2024-11-01 |
|
| NCT05287607 | N/A |
Unknown status |
Urinary Tract Infections|Protein Deficiency|Skin Abnormalities|Jaundice, Neonatal|Acute Kidney Injury|Protein C Deficiency|Cross Infection|Acute Respiratory Distress Syndrome|Neonatal Sepsis|Malaria|Sickle Cell Trait|Neuromyelitis Optica|Kidney Diseases|Anemia, Sickle Cell|Liver Failure, Acute |
2024-05-31 |